Lawmakers Urge HHS to Force Lilly to Reinstate 340B Discounts
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Dozens of Congressional lawmakers sent a bipartisan letter to HHS Secretary Robert F. Kennedy Jr. urging the Trump administration to force Eli Lilly to reinstate mandated 340B drug price discounts to participating hospitals.
- Eli Lilly stopped offering 340B discounts last month, citing its effort to reduce what it calls duplicate discounts, and targeted 50 larger hospital systems among approximately 1,000 hospitals that had not complied with a new claims-data policy announced earlier this year.
- Lilly maintained that roughly 70% of hospitals participating in the 340B program — more than 2,300 — had previously provided claims data under the new policy.
- The bipartisan lawmakers argued Lilly is failing to comply with federal law by eliminating the price breaks for hospitals that participate in the drug discount program but refused to hand over claims data.
Why it matters: This forces the Trump administration to choose between enforcing drugmaker compliance with the 340B statute or backing Lilly's claims-data policing strategy. Roughly 50 larger hospital systems already lost mandated price breaks after refusing to share claims data, a dispute that could ripple through the ~1,000 noncompliant hospitals and the 2,300+ already providing data.
